Scarica l'app Stockscreener
38.87
0.94%
-0.37
Dopo l'orario di chiusura:
38.45
-0.42
-1.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TGTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$39.24
Aprire:
$39.33
Volume 24 ore:
1.36M
Relative Volume:
0.65
Capitalizzazione di mercato:
$5.95B
Reddito:
$616.29M
Utile/perdita netta:
$447.18M
Rapporto P/E:
14.00
EPS:
2.7771
Flusso di cassa netto:
$-24.99M
1 W Prestazione:
-1.59%
1M Prestazione:
+1.46%
6M Prestazione:
+21.66%
1 anno Prestazione:
+13.52%
Intervallo 1D:
$38.53
$39.72
Intervallo di 1 settimana:
$38.20
$40.64
Portata 52W:
$25.28
$44.65
Tg Therapeutics Inc Stock (TGTX) Company Profile
Nome
Tg Therapeutics Inc
Settore
Industria
Telefono
(212) 554-4484
Indirizzo
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
38.87 | 6.01B | 616.29M | 447.18M | -24.99M | 2.7771 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-06 | Ripresa | H.C. Wainwright | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2024-10-29 | Iniziato | TD Cowen | Buy |
| 2023-08-02 | Aggiornamento | Goldman | Sell → Neutral |
| 2023-06-26 | Ripresa | Jefferies | Buy |
| 2022-05-20 | Iniziato | BofA Securities | Underperform |
| 2022-02-23 | Reiterato | B. Riley Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-20 | Iniziato | Goldman | Neutral |
| 2021-04-19 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-01 | Iniziato | JP Morgan | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-05 | Iniziato | Evercore ISI | Outperform |
| 2020-01-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-27 | Ripresa | B. Riley FBR | Buy |
| 2019-02-06 | Ripresa | Jefferies | Buy |
| 2018-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Ripresa | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Ripresa | H.C. Wainwright | Buy |
| 2017-04-25 | Iniziato | Jefferies | Buy |
| 2017-03-06 | Reiterato | FBR & Co. | Outperform |
| 2016-10-06 | Ripresa | Brean Capital | Buy |
| 2016-05-27 | Iniziato | SunTrust | Buy |
| 2015-12-01 | Iniziato | FBR Capital | Outperform |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-08-12 | Ripresa | H.C. Wainwright | Buy |
| 2015-06-19 | Reiterato | Brean Capital | Buy |
| 2014-12-11 | Reiterato | ROTH Capital | Buy |
| 2014-12-10 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tg Therapeutics Inc Borsa (TGTX) Ultime notizie
TG Therapeutics, Inc. (TGTX) Stock Analysis: Exploring a 23% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
TGTX stock rises 29% in 3 months: Here's what you should know - MSN
TGTX Q1 earnings miss, sales rise Y/Y, stock up on raised 2026 view - MSN
How Investors May Respond To TG Therapeutics (TGTX) Boosting 2026 Guidance On Stronger Briumvi Sales - Sahm
TGTX Technical Analysis | Trend, Signals & Chart Patterns | TG THERAPEUTICS INC (NASDAQ:TGTX) - ChartMill
TGTX stock hits fresh 52-week high – here’s why retail is bullish despite Q1 earnings miss - MSN
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know - sharewise.com
Earnings call transcript: TG Therapeutics Q1 2026 misses EPS expectations By Investing.com - Investing.com Nigeria
TG Therapeutics, Inc. (TGTX) Stock Analysis: Potential 21.52% Upside Sparks Investor Interest - DirectorsTalk Interviews
TG Therapeutics, Inc.Common Stock (NQ: TGTX - The Chronicle-Journal
Technical Reactions to TGTX Trends in Macro Strategies - Stock Traders Daily
TGTX Stock Price, Quote & Chart | TG THERAPEUTICS INC (NASDAQ:TGTX) - ChartMill
TG Therapeutics Stock Story Gains Interest In Nasdaq Index - Kalkine Media
TG Therapeutics' (NASDAQ:TGTX) Earnings Aren't As Good As They Appear - Yahoo Finance
Earnings call transcript: TG Therapeutics Q1 2026 misses EPS, stock surges - Investing.com UK
TG Therapeutics outlines $925M 2026 global revenue guidance while targeting ~$220M Q2 US BRIUMVI net revenue - MSN
Earnings call transcript: TG Therapeutics Q1 2026 misses EPS, stock surges By Investing.com - Investing.com Australia
Signal Says Which Biotech to Buy This Week - Schaeffer's Investment Research
A Look At TG Therapeutics (TGTX) Valuation After Record Q1 Revenue And Higher 2026 Guidance - Sahm
Why TG Therapeutics (TGTX) Is Up 27.4% After Raising 2026 Revenue Guidance On BRIUMVI Strength - Yahoo Finance
Assessing TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum - Yahoo Finance
TG THERAPEUTICS INC (NASDAQ:TGTX) Screens as Affordable Growth Play with Strong Revenue Surge and Discounted Valuation - ChartMill
MSN Money - MSN
TG Therapeutics (TGTX) Q1 2026 Results Put 66% Net Margin Narrative To The Test - Sahm
TG Therapeutics (TGTX) Q1 2026 Earnings Transcript - AOL.com
TGTX Stock Quote Price and Forecast - CNN
TGTX Reports Strong Q1 Revenue Growth and Upgraded Guidance - GuruFocus
Number of shareholders of TG Therapeutics, Inc. – LSX:A1JXW7 - TradingView
TG Therapeutics Stock 6-Day Winning Spree: Stock Climbs 28% - Trefis
6-Day Rally Sends TG Therapeutics Stock Up 28% - Trefis
TG Therapeutics Earnings Call Highlights Explosive Growth - The Globe and Mail
TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View - The Globe and Mail
Is Briumvi-Driven Earnings Growth Altering The Investment Case For TG Therapeutics (TGTX)? - Sahm
Tg Therapeutics Inc Azioni (TGTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):